A study to evaluate the use of homoeopathic medicine Selenium metallicum 6C in managing symptoms of enlarged prostate among elderly men.

Efficacy of Selenium metallicum 6C in Benign Prostatic Hyperplasia among elderly men, assessing International-Prostate Symptom Score: An open-label, single-arm, pilot trial. - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/05/110062

Enrollment

Registered

2026-05-05

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N401- Benign prostatic hyperplasia withlower urinary tract symptoms

Interventions

Intervention1: SELENIUM METALLICUM 6C: It will be designed to administer Selenium metallicum 6C to all the patients. Patients will be instructed to take single dose orally on a clean tongue on empty s

Eligibility

Inclusion criteria

Inclusion criteria: 1. Men aged 60-80 years with signs and symptoms of Benign Prostatic Hyperplasia. 2. International-Prostate Symptom Score in the range 8-19. 3. Prostate Serum Antigen (PSA) less than equal to 4 ng/ml. 4. Pelvic USG suggesting Prostate volume more than 35 cc.

Exclusion criteria

Exclusion criteria: 1. Patients with serious underlying medical condition such as severe renal, hepatic disease and prostatic carcinoma. 2. Complete retention of urine for more than 24 hours. 3. Recurrent urinary tract infection, neurogenic bladder, or urethral stricture. 4. Cases suffering from uncontrolled systemic illness or life-threatening conditions. 5. Patients with family history of Prostatic Carcinoma. 6. Those interested in opting for surgery in the next 6 months. 7. Cases already undergoing homeopathic treatment for any chronic purpose.

Design outcomes

Primary

Measure	Time frame
The change in International Prostate Symptom Score (I-PSS) from baseline to 6 weeks and 12 weeks following administration of Selenium metallicum 6C in patients diagnosed with benign prostatic hyperplasia.Timepoint: Baseline to 6 weeks and 12 weeks	—

Secondary

Measure	Time frame
1. The reduction of size of prostate gland and post-void residual urine volume, if any, will be recorded using USG-PELVIS at the end of 12 weeks. 2. Health-Related Quality of life (HRQoL) assessment using SF-36 Questionnaire score will be done at baseline and at the end of 12 weeks.Timepoint: Baseline to 12 weeks	—

Countries

India

Contacts

Public ContactDr Arijit Pal Choudhury

Pratap Chandra Memorial Homoeopathic Hospital and College

drarijitpalchoudhury@gmail.com9073129036

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026